Shots:
- Atavistik Bio has entered into a strategic research collaboration with Roche to discover & develop novel small molecules against multiple targets for cardiovascular, renal, and metabolic (CVRM) diseases, using Atavistik’s AMPS platform
- As per the deal, Atavistik Bio will be responsible for discovery & research activities for the collaboration targets, with Roche responsible for further preclinical & clinical development, regulatory, & commercialization activities
- Atavistik Bio will receive ~$70M upfront & ~$1.9B in additional research, development, & commercial milestone payments, & tiered royalties on future net sales
Ref: Globenewswire | Image: Atavistik Bio & Roche | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
